News
IMRN
1.090
+0.93%
0.010
Weekly Report: what happened at IMRN last week (0928-1002)?
Weekly Report · 2d ago
Weekly Report: what happened at IMRN last week (0921-0925)?
Weekly Report · 09/28 10:03
Weekly Report: what happened at IMRN last week (0914-0918)?
Weekly Report · 09/21 10:03
Weekly Report: what happened at IMRN last week (0907-0911)?
Weekly Report · 09/14 10:07
3 Penny Stocks to Watch Today, September 8
TipRanks · 09/08 14:49
Weekly Report: what happened at IMRN last week (0831-0904)?
Weekly Report · 09/07 10:02
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 09/04 17:06
Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results
Benzinga · 09/04 16:13
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August
Benzinga · 09/04 14:07
Immuron Stock Surges Friday: What's Driving the Action?
Benzinga · 09/04 13:11
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 09/04 12:05
Market-Moving News for September 4th
Benzinga · 09/04 11:22
Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up
NASDAQ · 09/04 11:02
Immuron to launch Proibs in the U.S.
TipRanks · 09/04 10:05
Weekly Report: what happened at IMRN last week (0824-0828)?
Weekly Report · 08/31 10:08
Immuron FY26 Revenue Rises 6% As Net Loss Narrows And Cash Surges
NASDAQ · 08/28 17:06
Immuron reports FY results
Seeking Alpha · 08/28 10:12
Immuron Reports FY26 Preliminary Results
Barchart · 08/28 05:00
Weekly Report: what happened at IMRN last week (0817-0821)?
Weekly Report · 08/24 10:08
Weekly Report: what happened at IMRN last week (0810-0814)?
Weekly Report · 08/17 10:09
More
Webull provides a variety of real-time IMRN stock news. You can receive the latest news about Immuron Ltd through multiple platforms. This information may help you make smarter investment decisions.
About IMRN
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), and IMM-529.